TRENDING TOPICS
3055 articles found for "investing"
Radiopharmaceutical developer Aktis Oncology raised $318 million in the first biotech IPO of 2026, with Eli Lilly taking a $100 million stake. The strong debut signals renewed investor appetite for biotech risk.
Warren Buffett's favorite market metric has hit 224%, the highest level ever recorded. Here's what it means for investors and why timing matters less than you think.
Industry executives and analysts forecast Bitcoin could trade anywhere from $75,000 to $225,000 in 2026, reflecting the extreme volatility that continues to define the asset class.
Chip stocks rallied to kick off 2026 as Bank of America forecasts the semiconductor industry will finally cross $1 trillion in annual sales. Here are the stocks leading the charge.
Regional bank stocks are leading the financial sector in early 2026 as Fed rate cuts improve net interest margins and deregulation expectations fuel a wave of M&A activity.
The 44th annual JPMorgan Healthcare Conference kicks off Monday in San Francisco. Here's what biotech and pharma investors need to watch.
The Dow Jones Industrial Average has crossed 49,000 for the first time, driven by a rotation into 'old economy' stocks. Here's what's behind the blue-chip renaissance.
The Russell 2000 hit new all-time highs as investors rotate out of big tech and into small-cap stocks. The 'January Effect' is in full swing with the index up over 6% in the first week of 2026.
After a decade of U.S. dominance, international stocks outperformed by nearly 13 percentage points in 2025. Here's what drove the shift and what it means for 2026.
Nvidia has visibility to half a trillion dollars in revenue through 2026 from its Blackwell and Rubin platforms. As the AI chip king prepares for CES, analysts see continued dominance ahead.
After raising $4 billion at a $134 billion valuation, Databricks may be preparing for one of tech's largest IPOs. CEO Ali Ghodsi hasn't ruled out a 2026 listing.
From Vanda Pharmaceuticals to Denali Therapeutics, here are the FDA decisions in early 2026 that could move biotech stocks—for better or worse.